Jubilant Ingrevia hits 14-quarter revenue high, guides for more
Q4 sales reached ₹1,179 cr, the highest in three and a half years. Volume drove the growth, not price.
— 4 earlier stories on Jubilant Ingrevia Ltd. →What's new
- Q4 consolidated revenue rose 12% year-on-year to ₹1,179 cr, driven by 10% volume growth across all segments.
- EBITDA increased 11% to ₹172 cr; net profit grew 17% to ₹86 cr.
- The company guided for sequential revenue and EBITDA growth from Q1 FY27, led by specialty chemicals and nutrition.
Why this matters
This is the strongest quarter the specialty chemicals firm has posted in over three years. The guidance for continued sequential expansion is an explicit signal from management that the momentum is not a one-quarter event. The volume-driven growth, in particular, suggests underlying demand is holding, not just pricing power.
What we're watching
- The revenue ramp from the new agro CDMO facility in Q1 FY27.
- Sustainability of the 10% volume growth trend amid global supply-chain noise.
- Management's ability to hold the 15% EBITDA margin as costs fluctuate.
The full read
Jubilant Ingrevia just delivered its strongest quarter in 14. Revenue hit ₹1,179 crore, up 12% year-on-year, and it wasn't price doing the work. Volume rose 10% across every segment. EBITDA climbed to ₹172 crore, net profit jumped 17% to ₹86 crore, and the board is paying out ₹2.50 a share as a final dividend. The specialty chemicals maker also navigated Middle East supply snags without halting production and began dispatching from its new agro CDMO plant. Now for the forward view: management is calling for sequential growth in both sales and profit to start the next financial year. That is a specific, confident forecast for a cyclical industry. The open question is whether the new CDMO facility can scale fast enough to underpin that call.
Questions answered
- Why is this quarter's revenue figure significant?
- At ₹1,179 cr, it is Jubilant Ingrevia's highest quarterly revenue in 14 quarters, breaking a multi-year streak.
- What drove the top-line growth?
- The 12% year-on-year revenue increase was primarily volume-led, with the company reporting 10% volume growth across all of its business segments.
- How did profitability track revenue?
- Net profit rose a sharper 17% to ₹86 cr, slightly outpacing the 11% EBITDA growth to ₹172 cr. Margins held steady at 15%.
- What specific operational challenges did the company highlight?
- It successfully managed supply disruptions from the Middle East without any production loss, a non-trivial feat for a chemicals manufacturer dependent on global logistics.
- What does the dividend payout look like for the full year?
- The board recommended a final dividend of ₹2.50 per share, bringing the total FY26 payout to ₹5 per share.
Jubilant Ingrevia Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLINGREA →- 26 May 2026 · 3:00 PM IST Jubilant Ingrevia hits 14-quarter revenue high, guides for more
- 38d ago Jubilant Ingrevia's call transcript quantifies a ₹3,500 cr CDMO pipeline
- 41d ago Jubilant Ingrevia's $300M agro client faces financial distress
- 41d ago Jubilant Ingrevia posts highest profit in 14 quarters on volume recovery
- 41d ago Jubilant Ingrevia's FY26 profit grows 10.6%. The numbers were expected.